Silverarc Capital Management, LLC Prothena Corp Public LTD CO Transaction History

Silverarc Capital Management, LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$47.3 - $70.6 $1.09 Million - $1.63 Million	-23,092 Reduced 46.44%	26,629 $1.28 Million
Q2 2023 Aug 14, 2023	BUY	$48.26 - $78.59 $2.4 Million - $3.91 Million	49,721 New	49,721 $3.39 Million
Q4 2022 Feb 14, 2023	SELL	$52.05 - $65.0 $1.99 Million - $2.49 Million	-38,294 Reduced 34.81%	71,706 $4.32 Million
Q3 2022 Oct 28, 2022	BUY	$25.16 - $60.63 $2.77 Million - $6.67 Million	110,000 New	110,000 $6.67 Million

184

42.7M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $714M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Silverarc Capital Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Silverarc Capital Management, LLC with notifications on news.